The anticancer effects of the anti‐CD47 antibody in mouse models were synergistically enhanced by combining with another anticancer drug such as rituximab in a NHL model18 or azacytidine in an AML model,19 furnishing a rationale for combination clinical trials. This evidence concerns the gene CD47 and non-Hodgkin lymphoma.